Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.7 USD | +5.36% | +7.61% | -43.48% |
May. 30 | Evercore ISI Cuts Price Target on Editas Medicine to $7 From $15, Maintains In Line Rating | MT |
May. 14 | Editas Medicine Insider Bought Shares Worth $253,868, According to a Recent SEC Filing | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-43.48% | 445M | C+ | ||
+45.26% | 56.65B | B- | ||
-7.11% | 39.44B | B | ||
+39.19% | 39.03B | A | ||
-11.17% | 26.86B | C | ||
+12.22% | 26.75B | B- | ||
-21.72% | 19.03B | B | ||
+1.39% | 12.28B | B+ | ||
+24.23% | 12.26B | B+ | ||
+27.37% | 12.04B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EDIT Stock
- Ratings Editas Medicine, Inc.